The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics
Abstract
Currently available serum biomarkers are insufficiently reliable to distinguish patients with epithelial ovarian cancer (EOC) from healthy individuals. Metabonomics, the study of metabolic processes in biologic systems, is based on the use of 1 H‐NMR spectroscopy and multivariate statistics for biochemical data generation and interpretation and may provide a characteristic fingerprint in disease. In an effort to examine the utility of the metabonomic approach for discriminating sera from women with EOC from healthy controls, we performed 1 H‐NMR spectroscopic analysis on preoperative serum specimens obtained from 38 patients with EOC, 12 patients with benign ovarian cysts and 53 healthy women. After data reduction, we applied both unsupervised Principal Component Analysis (PCA) and supervised Soft Independent Modeling of Class Analogy (SIMCA) for pattern recognition. The sensitivity and specificity tradeoffs were summarized for each variable using the area under the receiver‐operating characteristic (ROC) curve. In addition, we analyzed the regions of NMR spectra that most strongly influence separation of sera of EOC patients from healthy controls. PCA analysis allowed correct separation of all serum specimens from 38 patients with EOC (100%) from all of the 21 premenopausal normal samples (100%) and from all the sera from patients with benign ovarian disease (100%). In addition, it was possible to correctly separate 37 of 38 (97.4%) cancer specimens from 31 of 32 (97%) postmenopausal control sera. SIMCA analysis using the Cooman's plot demonstrated that sera classes from patients with EOC, benign ovarian cysts and the postmenopausal healthy controls did not share multivariate space, providing validation for the class separation. ROC analysis indicated that the sera from patients with and without disease could be identified with 100% sensitivity and specificity at the 1 H‐NMR regions 2.77 parts per million (ppm) and 2.04 ppm from the origin (AUC of ROC curve = 1.0). In addition, the regression coefficients most influential for the EOC samples compared to postmenopausal controls lie around δ3.7 ppm (due mainly to sugar hydrogens). Other loadings most influential for the EOC samples lie around δ2.25 ppm and δ1.18 ppm. These findings indicate that 1 H‐NMR metabonomic analysis of serum achieves complete separation of EOC patients from healthy controls. The metabonomic approach deserves further evaluation as a potential novel strategy for the early detection of epithelial ovarian cancer. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nicholson, J. K., Lindon, J. C., & Holmes, E. (1999) · Xenobiotica · doi:10.1080/004982599238047 · Cited by 3,895
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Structure Determination of Organic Compounds
Pretsch, E., Bühlmann, P., & Affolter, C. (2000) · Springer eBooks · doi:10.1007/978-3-662-04201-4 · Cited by 3,026
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Metabonomics: a platform for studying drug toxicity and gene function
Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd728 · Cited by 1,914
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Orthogonal signal correction of near-infrared spectra
Wold, S., Antti, H., Lindgren, F., & Öhman, J. (1998) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/s0169-7439(98)00109-9 · Cited by 1,089
Brindle, J. T., Antti, H., Holmes, E., Tranter, G., Nicholson, J. K., Bethell, H. W. L., Clarke, S., Schofield, P. M., McKilligin, E., Mosedale, D. E., et al. (2002) · Nature Medicine · doi:10.1038/nm1202-802 · Cited by 1,029
750 MHz 1H and 1H-13C NMR Spectroscopy of Human Blood Plasma
Nicholson, J. K., Foxall, P. J. D., Spraul, M., Farrant, R. D., & Lindon, J. C. (1995) · Analytical Chemistry · doi:10.1021/ac00101a004 · Cited by 1,021
Tables of Spectral Data for Structure Determination of Organic Compounds
Pretsch, E., Clerc, T., Seibl, J., & Simon, W. (1989) · Chemical Laboratory Practice · doi:10.1007/978-3-662-10207-7 · Cited by 1,011
Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures
Fan, T. W.-M. (1996) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/0079-6565(95)01017-3 · Cited by 753
Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers
Xu, Y. (1998) · JAMA · doi:10.1001/jama.280.8.719 · Cited by 637
High resolution proton magnetic resonance spectroscopy of biological fluids
Nicholson, J. K., & Wilson, I. D. (1989) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/0079-6565(89)80008-1 · Cited by 625
Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., & Major, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221501 · Cited by 583
Screening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
Kim, J.-H. (2002) · JAMA · doi:10.1001/jama.287.13.1671 · Cited by 480
Metabonomics: Metabolic processes studied by NMR spectroscopy of biofluids
Lindon, J. C., Nicholson, J. K., Holmes, E., & Everett, J. R. (2000) · Concepts in Magnetic Resonance · doi:10.1002/1099-0534(2000)12:5<289::aid-cmr3>3.0.co;2-w · Cited by 460
Pattern recognition methods and applications in biomedical magnetic resonance
Lindon, J. C., Holmes, E., & Nicholson, J. K. (2001) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/s0079-6565(00)00036-4 · Cited by 425
Lindon, J. C., Nicholson, J. K., & Everett, J. R. (1999) · Annual Reports on NMR Spectroscopy · doi:10.1016/s0066-4103(08)60035-6 · Cited by 395
The Efficacy of Transvaginal Sonographic Screening in Asymptomatic Women at Risk for Ovarian Cancer
van Nagell, J. R., DePriest, P. D., Reedy, M. B., Gallion, H. H., Ueland, F. R., Pavlik, E. J., & Kryscio, R. J. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5816 · Cited by 345
Gavaghan, C. L., Holmes, E., Lenz, E., Wilson, I. D., & Nicholson, J. K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02147-5 · Cited by 321
Chemometric Models for Toxicity Classification Based on NMR Spectra of Biofluids
Holmes, E., Nicholls, A. W., Lindon, J. C., Connor, S. C., Connelly, J. C., Haselden, J. N., Damment, S. J. P., Spraul, M., Neidig, P., & Nicholson, J. K. (2000) · Chemical Research in Toxicology · doi:10.1021/tx990210t · Cited by 276
Brindle, J. T., Nicholson, J. K., Schofield, P. M., Grainger, D. J., & Holmes, E. (2003) · The Analyst · doi:10.1039/b209155k · Cited by 191
Holmes, E., Nicholson, J. K., & Tranter, G. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000158x · Cited by 177
1H NMR spectroscopy of human blood plasma
Ala-Korpela, M. (1995) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/0079-6565(95)01013-0 · Cited by 168
Pepe, M. S. (1997) · Biometrika · doi:10.1093/biomet/84.3.595 · Cited by 142
Coomans, D. H., Broeckaert, I., Derde, M. P., et al. (1984) · Computers and Biomedical Research · doi:10.1016/0010-4809(84)90002-8 · Cited by 77
Zhang, Z., Barnhill, S. D., Zhang, H., Xu, F., Yu, Y., Jacobs, I. J., Woolas, R. P., Berchuck, A., Madyastha, K. R., & Bast, R. C. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5320 · Cited by 76
Generating longitudinal screening algorithms using novel biomarkers for disease.
McIntosh, M. W., Urban, N. D., & Karlan, B. Y. (2002) · PubMed · Cited by 60
Cited by
Trygg, J., Holmes, E., & Lundstedt, T. (2007) · Journal of Proteome Research · doi:10.1021/pr060594q · Cited by 1,273
Clinical Applications of Metabolomics in Oncology: A Review
Spratlin, J. L., Serkova, N. J., & Eckhardt, S. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1059 · Cited by 753
Roberts, L. D., Souza, A. L., Gerszten, R. E., & Clish, C. B. (2012) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb3002s98 · Cited by 695
Metabolomics-based methods for early disease diagnostics
Gowda, G. N., Zhang, S., Gu, H., Asiago, V., Shanaiah, N., & Raftery, D. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.5.617 · Cited by 692
Metabolomics: A Global Biochemical Approach to Drug Response and Disease
Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094715 · Cited by 670
Metadata
- Authors
- Odunsi, K., Wollman, R. M., Ambrosone, C. B., Hutson, A., McCann, S. E., Tammela, J., Geisler, J. P., Miller, G., Sellers, T., Cliby, W., Qian, F., Keitz, B., Intengan, M., Lele, S., & Alderfer, J. L.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-12-08
- Volume
- 113
- Issue
- 5
- Pages
- 782-788
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1978417221
- Cited by
- 317
- References
- 31
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.